Brought to you by 
Bayer licenses Natrecor from Scios for $60mm
Jun 1998
Executive Summary
Bayer has licensed worldwide rights to Scios's congestive heart failure (CHF) drug Natrecor (nesiritide). Bayer will pay (uf)$20mm cash upfront, up to an additional $40mm upon US, European, and Japanese regulatory milestones, plus sales royalties.
Deal Industry
-
Biotechnology
- Large Molecule
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R+D and Marketing-Licensing
- Co-Promotion
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer licenses Natrecor from Scios for $60mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice